Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial

🏆 Top 20📊 OpenAlex

Most Cited Paper

in Heart Failure Treatment and Management

18 Months Post-Publication

Class of 2026

“Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial”

AuthorsRichard E Pratley et al.

Richard E. Pratley

JournalJournal of the American College of Cardiology

AdventHealth Translational Research Institute

Citations86

DOI10.1016/j.jacc.2024.08.004

A research intelligence initiative by Pepkio

pri.pepkio.com

Topics

semaglutide · GLP-1 receptor agonist · type 2 diabetes · chronic kidney disease · Heart failure · FLOW trial · Cardiovascular mortality · Estimated glomerular filtration rate · kidney replacement therapy · Worsening heart failure events · NYHA functional class · Heart failure with reduced ejection fraction · composite outcome · subcutaneous administration · hazard ratio

Share on X

Cite this ranking

Pepkio Research Index (PRI). Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026. https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026. Accessed 2026-08-20.

Methodology
Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459